Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

CRANFORD, N.J., Dec. 10, 2018 /PRNewswire/ -- Citius Pharmaceuticals CTXR, based in New Jersey, focused on specialty pharmaceuticals in adjunctive cancer care and critical care, today announced that the December 6, 2018  presentation from Myron Holubiak, CEO,  is now available for on-demand viewing at VirtualInvestorConferences.com.

www.virtualinvestorconferences.com . (PRNewsFoto/OTC Markets Group Inc.)" alt="View investor presentations 24/7 at www.virtualinvestorconferences.com . (PRNewsFoto/OTC Markets Group Inc.)">

LINK:  https://tinyurl.com/126postpr

Citius Pharmaceutical's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

Recent Company Highlights

• The Citius Scientific Advisory Board (SAB) meeting was held on October 4, 2018 to discuss the progress of the Mino-Lok® pivotal phase 3 trial. Twenty investigational sites have been initiated with another 15 in "start up" mode awaiting final IRB approvals or contract signatures.
• On October 2, 2018, Citius received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") issued United States Patent Number 10/086,114 entitled "Antimicrobial Solutions with Enhanced Stability". Citius also received official notification from MDACC that the European Patent Application (No. 16806326.1) for Mino-Lok with Enhanced Stability was published (September 12, 2018) under serial number 3370794.
• Citius has selected a higher potency corticosteroid in its steroid/anesthetic topical formulation program for the treatment of hemorrhoids. The new formulation, CITI-002, will combine lidocaine with a higher potency corticosteroid. The Company held a Type C meeting with FDA to discuss the results of the Phase 2a study and obtained the Agency's view on development plans to support the potential formulation change. The pre-clinical and clinical development programs for CITI-002 will be similar to those conducted in CITI-001 development. 

Learn more about the event at www.VirtualInvestorConferences.com.

About Citius Pharmaceuticals

Citius Pharmaceuticals CTXR is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius product candidates aim to offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is currently advancing two proprietary product candidates, our Mino-Lok® product and CITI-002, a corticosteroid/lidocaine formulation. Citius believes the markets for its product candidates are large and underserved by the current standard of care.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

SOURCE Citius Pharmaceuticals